Compare Heron Therapeutics Inc (HRTX) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Moody's Corporation — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Moody's Corporation trades at $490.77 (market cap $88.28B). The key difference: Moody's Corporation is far larger — about 965.2× Heron Therapeutics Inc's market cap, and Moody's Corporation pays a 0.82% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MCO | |
|---|---|---|
Market Cap | $91.46M | $88.28B |
Sector | Health | Financials |
52-Week High | $1.96 | $539.61 |
52-Week Low | $0.39 | $412.23 |
Enterprise Value | $189.36M | $94.08B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
Moody's Corporation (MCO) trades at $490.54, down 3.97% in the last session, with strong fundamentals including 31.69% net income margin and 74.54% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, while recent earnings consistently beat expectations. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, with Q2 2026 results expected on July 22, 2026.
MCO presents a compelling investment case with premium valuation metrics (P/E 36.25) justified by exceptional profitability and market dominance. Key risks include valuation sensitivity and dependence on debt issuance cycles. Analyst consensus remains bullish with $558.14 price target, representing 13.8% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
